In May, VCBeat published its 2026 Future Healthcare Top 100 lists. Innogen was included in the ‘Top 50 Listed Healthcare Companies for Innovation’ for its sustained R&D capabilities, differentiated portfolio and international development potential. The ranking evaluates Chinese listed healthcare companies across R&D investment, innovative pipelines, technology platforms and international development to assess innovation and long-term value. Inclusion reflects industry recognition of Innogen's research capabilities, innovation and global potential.
Focused on developing and commercializing innovative medicines for metabolic disease, Innogen prioritizes clinical value and advances R&D and international development around the characteristics of Chinese patients and unmet clinical needs worldwide. Its independently developed human-derived, ultra-long-acting GLP-1 receptor agonist efsubaglutide alfa is approved for type 2 diabetes in mainland China and Macau. Clinical development across multiple indications, including obesity and MASH, is progressing internationally.
To address treatment needs in overweight and obesity, Innogen is systematically evaluating efsubaglutide alfa's potential in weight management, body composition and metabolic fat deposition. In the Chinese Phase IIb overweight/obesity study, the 20 mg once-weekly group showed an approximately 45.3% increase in muscle-to-fat ratio and a 46.9% reduction in liver fat. These findings suggest differentiated development potential for fat loss, muscle preservation and improvement in metabolic fat deposition.
Early findings also showed a half-life of approximately 280 hours in patients with obesity, providing a pharmacokinetic basis for investigating longer dosing intervals. A Phase II trial in Australia is further evaluating the feasibility of once-monthly administration.
Wenjie Xu, Innogen's senior vice president and chief business officer, said: “Inclusion in the Top 50 Listed Healthcare Companies for Innovation recognizes Innogen's R&D capabilities and long-term plans. China's innovative-drug industry is becoming more closely connected with global innovation. Products with clinical value and differentiated advantages continue to attract interest from international markets and investors. Innogen will remain focused on metabolic disease and patient needs, advance its core product and international development, accelerate research translation and work to provide more high-quality treatment options for patients worldwide.”
Note: Efsubaglutide alfa is currently approved for type 2 diabetes. Obesity and weight-loss indications remain under clinical investigation and are not approved for marketing. This content provides company R&D updates and industry information only; it does not constitute drug advertising, treatment advice or a promise of efficacy. Prescription medicines should be purchased with a physician's prescription and used under medical supervision.
About Innogen
Founded in 2014, Innogen (HK.2591) develops and commercializes innovative medicines for metabolic diseases. Its independently developed pipeline covers indications including type 1 diabetes (T1D), obesity, metabolic dysfunction-associated steatohepatitis (MASH) and Alzheimer’s disease (AD), with global intellectual property and patent coverage. Its core product, efsubaglutide alfa, is an independently developed, new-generation, human-derived, ultra-long-acting GLP-1 receptor agonist approved in mainland China and Macau for type 2 diabetes and included in the National Drug Reimbursement List for Basic Medical Insurance, Maternity Insurance and Work Injury Insurance (2025 edition). It has entered global development and registration, with the aim of providing better treatment options for patients worldwide. For more information, visit: www.innogenpharm.com.